Immuneering Corp

IMRXNASDAQ · USD
4.27USD0.00 (-1.62%)
232

Immuneering Corp (IMRX) Covered Calls

As of September 25, 2026, IMRX has 7 covered call opportunities in the coming three months. Return ranges from 16.4 to 76.3% until expiration. Annualized return ranges from 33.8 to 473.6%. The nearest expiration is November 20, 2026. Maximum potential profit is $331.

Read more

Running IMRX covered calls helps you generate consistent income from Immuneering Corp's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Immuneering Corp involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best IMRX covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if IMRX stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling IMRX covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Immuneering Corp covered call is worth writing.

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Income-focused investors, long-term IMRX holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling IMRX covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Immuneering Corp covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile—
  • Market cap (M$)276
  • 52 weeks high-49.65%
  • 52 weeks low10.62%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$17.17
    302.11% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-11
  • P/E—
  • Future P/E—
  • EPS (ttm)-1.03
  • EPS growth next 5 years3.70%

As of September 25, 2026

2026-11-20577.5072.810.050.25321.0073.96473.62-1.15+0.171610.20
2027-02-191487.5072.810.154.70331.0076.27188.09-3.46+0.75804.55
2027-05-212397.5072.810.100.70326.0075.12114.72-2.30+0.3100.60
2026-11-20575.0015.210.050.4571.0016.36104.76-1.15+0.362190.40
2027-02-191485.0015.210.451.20111.0025.5863.08-10.37+0.54470.75
2027-01-151135.0015.210.051.3071.0016.3652.84-1.15+0.505451.25
2027-05-212395.0015.210.304.9096.0022.1233.78-6.91+0.7934.60

As of September 25, 2026

Sell covered calls with the data behind you

Find the best IMRX covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial